Floatz logo

LENVATINIB

Gliosarcoma

National Cancer Institute (NCI)Small moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
81/ 100

Competitive context

39 Active assets in the Gliosarcoma cohort.

Asset / SponsorPhaseRating
Irinotecan
RTOG Foundation, Inc.
Phase 3BB
(+)-VINCRISTINE
RTOG Foundation, Inc.
Phase 3BB
Cyclophosphamide
Mayo Clinic
Phase 2BB
DEXAMETHASONE
Pediatric Brain Tumor Consortium
Phase 2BB
Ipilimumab
University College, London
Phase 2/3BB

View all 50 →

Same molecule, other indications

LENVATINIB is also rated in:

Primary Peritoneal Cavity CancerDormant
BBB
Indicative ·
73 / 100
View asset →
Stage IIB Breast CancerDormant
BBB
Indicative ·
73 / 100
View asset →
portal vein thrombosisDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →